Analysis of Antibody Response to HPV 16 and HPV 18 Antigens in Tunisian Patients

Achour, M.; Kahla, Saloua; Zeghal, D; Kochbati, L.; Maâlej, M.; Zouari, F.; Oueslati, Ridha

doi:10.1089/vim.2008.0009

Cited by 5 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPV seroprevalence data were available from Mali (15), Nigeria (16), South Africa (17-21), and Tunisia (22,23); age-trend data are shown in supplementary Figure 1A-B (online). HPV 16 seroprevalence was lowest in South African children at 2.9%, (age range 8-12 years) (18), and highest in clinic-based control women from Cape Town, South Africa at 60% (18-30 years) (19).…”

Section: Resultsmentioning

confidence: 99%

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

Tiggelaar¹,

Lin²,

Viscidi³

et al. 2012

Journal of Adolescent Health

View full text Add to dashboard Cite

Purpose Global data on human papillomavirus serological and DNA prevalence are essential to optimize HPV prophylactic vaccination strategies. Methods We conducted a global review of age-specific HPV antibody and studies with both antibody and DNA prevalence for HPV types 16, 18, 6 and 11. Results One hundred-seventeen studies were included; participants’ ages ranged from several hours to over 90 years. HPV 16 seroprevalence was generally higher in Africa, Central and South America, and North America, more prevalent among women than men, and peaked around ages 25-40 years. HPV 18 seroprevalence was generally lower than HPV 16 with a later age peak. Data were limited for HPV 6 and 11, which both peaked at ages similar to HPV 18. In 9-26 year-old females, HPV 16 seroprevalence ranged from 0-31% in North America, 21-30% in Africa, 0-23% in Asia/Australia, 0-33% in Europe, and 13-43% in Central and South America. HPV 16/18 DNA prevalence peaked 10-15 years before corresponding HPV 16/18 antibody prevalence. Conclusions Females within the HPV-vaccine eligible age group (9-26 years) had a range of dual HPV 16 DNA and serology negativity from 81-87%, whereas 90-98% were HPV 16 DNA negative. Serology and DNA data are lacking worldwide for females younger than age 15 years, the prime target group for vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

Tiggelaar¹,

Lin²,

Viscidi³

et al. 2012

Journal of Adolescent Health

View full text Add to dashboard Cite

show abstract

“…Cervical cancer is the second most common cancer among women worldwide, with about 470,000 newly diagnosed cases and almost 250,000 deaths every year [1,2]. Cervical cancer is the leading cause of death from cancer in many low-resource countries [3].…”

Section: Introductionmentioning

confidence: 99%

Cooperation of decay-accelerating factor and membrane cofactor protein in regulating survival of human cervical cancer cells

et al. 2009

View full text Add to dashboard Cite

BackgroundDecay-accelerating factor (DAF) and membrane cofactor protein (MCP) are the key molecules involved in cell protection against autologus complement, which restricts the action of complement at critical stages of the cascade reaction. The cooperative effect of DAF and MCP on the survival of human cervical cancer cell (ME180) has not been demonstrated.MethodsIn this study we applied, for the first time, short hairpin RNA (shRNA) to knock down the expression of the DAF and MCP with the aim of exploiting complement more effectively for tumor cell damage. Meanwhile, we investigated the cooperative effects of DAF and MCP on the viability and migration, moreover the proliferation of ME180 cell.ResultsThe results showed that shRNA inhibition of DAF and MCP expression enhanced complement-dependent cytolysis (CDC) up to 39% for MCP and up to 36% for DAF, and the combined inhibition of both regulators yielded further additive effects in ME180 cells. Thus, the activities of DAF and MCP, when present together, are greater than the sum of the two protein individually.ConclusionThese data indicated that combined DAF and MCP shRNA described in this study may offer an additional alternative to improve the efficacy of antibody-and complement-based cancer immunotherapy.

show abstract

“…Cervical cancer is the second most common cancer among women worldwide, with approximately 500,000 diagnosed cases and 250,000 deaths every year. 25 Cervical cancer is the leading cause of death from cancer in many developing countries. 26 This high incidence, coupled with the lack of effective therapies to treat cervical tumors, creates a pressing need for more efficient therapeutic methods.…”

Section: Discussionmentioning

confidence: 99%

Effect of ex vivo-expanded γδ-T cells combined with galectin-1 antibody on the growth of human cervical cancer xenografts in SCID mice

Wang²,

Zhou³

2010

CIM

View full text Add to dashboard Cite

Objective: To investigate the antitumor activity of ex vivo-expanded γδ-T cells derived from tumor-infiltrating lymphocytes(γδTILs) from cervical cancer patients when combined with galectin-1 antibody and studied both in vitro and in vivo. Methods: The presence of γδTILs in cervical cancer specimens was detected by immunohistochemistry and γδTILs were expanded using the solid-phase antibody method. The expression of galectin-1 by the human cervical cancer cell line, SiHa, was measured by Western blot and ELISA. In vitro cytotoxic activities of expanded γδTILs, with or without galectin-1 inhibitor, were determined using the LDH-release test. In vivo antitumor activity of γδTILs, combined with galectin-1 antibody, was evaluated using the SCID mouse model. Results: γδTILs existed in the cervical cancer and the percentage of TCRγδ+ cells in γδTILs after ex vivo expansion was 91.2±1.2% detected by flow cytometry. SiHa cell expressed and secreted galectin-1 as measured by Western blot and ELISA. Expanded γδTILs from human cervical cancer demonstrated marked cytotoxicity to SiHa or Hela cells. In comparison with non-treated group, the cytotoxicity of γδ TILs towards SiHa or Hela cell was significantly increased when effector and target cells were incubated with either lactose or galectin-1 antibody at E/T ratio of 1:1 (p < 0.05). γδTILs, in combination with galectin-1 antibody treatment, significantly suppressed the growth of xenografts in SCID mice, in comparison with all other groups (p < 0.05). γδTILs alone also showed the ability to inhibit tumour growth in vivo, but were more efficient when combined with specific antibody (p < 0.05). Conclusion: Taken together, our results suggest that γδ-T cells, combined with galectin-1 antibody treatment, could be a more effective adoptive immunotherapy for patients with cervical cancer than traditional adoptive immunotherapy methods.

show abstract

Analysis of Antibody Response to HPV 16 and HPV 18 Antigens in Tunisian Patients

Abstract: Antibody detection depends on the type of antigen, and is well correlated with international scientific findings. The differences in antibody response between patients with inflammation and patients with cervical cancer were significant.

Cited by 5 publications

References 22 publications

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

Cooperation of decay-accelerating factor and membrane cofactor protein in regulating survival of human cervical cancer cells

Effect of ex vivo-expanded γδ-T cells combined with galectin-1 antibody on the growth of human cervical cancer xenografts in SCID mice

Contact Info

Product

Resources

About